Before we witness the stabilization of economic growth in Europe and North America, Asia Pacific is estimated to bounce back progressively with countries such as China, India, South Korea and Japan witnessing more opportunities to recover from the losses sustained during COVID-19.
Being the biggest market in Eastern Europe, Russia is estimated to take the lowest hit, offering a sigh of relief to the businesses operating in the country. Whereas, GCC is estimated to observe low investments due to the sliding prices of crude oil.
We evaluate the strategies and commitment of the Giant Players in the market towards creating products and services that customers value and rely on.
In an attempt to control and eliminate the surge of coronavirus cases and meet the demand for required medical devices along with providing efficient medical services, there is a drastic shift of investments from authoritative bodies towards the healthcare sector. Where the aftermath of this pandemic may take years to be measured, Research Nester estimates notable expansion of e-health, gaming, and media and entertainment industries till the whole situation is contained and the plan of action for the recovery process is determined. There is an estimated probability of the growth in businesses going back a year if the condition is controlled in the next 2-3 months. Request Insights
IN THE NEWSIn April 2020, Novartis declared that its medicine, named Kymriah, has received the designation of Regenerative Medicine Advanced Therapy (RMAT) by the US FDA.
In November 2020, Stryker announced that it had completed the acquisition of the multinational medical device company, Wright Medical Group N.V. This acquisition will enable Stryker to enhance its global market position and reach more patients.
The global regenerative medicine market achieved a revenue of USD 34,270.0 Million in 2020 and is estimated to garner USD 167,500.0 Million by the end of 2029, by growing at a CAGR of 16.43% over the forecast period i.e., 2021-2029. The growth of the market can be attributed to the increasing incidence of cancer & diabetes, along with the rising incidences of cardiovascular diseases. According to the statistics by the World Health Organization (WHO), Europe accounted for 23.4% of the global cancer cases and 20.3% of the cancer deaths in the year 2018. Further, the statistics also stated that America had 13.3% of the global population, out of which, cancer incidences accounted for 21.0% and mortality due to cancer was registered to 14.4% in the same year. Additionally, the percentage of cancer deaths in Asia and in Africa, which registered to 57.3% and 7.3% respectively, were higher than the percentage of incident cases in both the nations with 48.4% and 5.8% respectively. The number of cancer patients worldwide is anticipated to grow further during the forthcoming decade, and in turn drive the demand for regenerative medicines. The growing number of diabetic patients globally is further estimated to contribute to the growth of the global regenerative medicine market during the forecast period. According to the statistics by the International Diabetes Federation, health expenditure caused due to diabetes around the globe was at least USD 760 Billion in the year 2019. Moreover, in the same year, deaths caused due to diabetes was registered to 4.2 Million. Further, around 463 Million adults between the age 20years and 79 years were living with diabetes. The high number of diabetes patients around the world is further raising the demand for regenerative medicines, which in turn is expected to drive the market growth.
Regionally, the global regenerative medicine market is segmented into five major regions including North America, Asia Pacific, Europe, Latin America, and the Middle East & Africa. Among the markets in these regions, the market in North America is estimated to hold leading market share throughout the forecast period and further attain a revenue of USD 69,194.25 Million in 2029. The market in Europe is projected to hold second leading stance and further garner a revenue of USD 56,682.0 Million in 2029 owing to the increasing cases of oncology and heart related diseases. In North American region, the United States is projected to generate significant growth opportunities for the market growth by attaining a revenue of USD 17,406.6 Million in 2021. The market in the U.S. is expected to hold 84.78% of the market share of the regenerative medicines market in North America in 2029, majorly owing to presence of major market players across U.S., such as, Integra LifeSciences Corporation, Sangamo, Zimmer Biomet and others, along with the presence of a strong healthcare infrastructure. The growing incidences of diseases related to oncology and cardiology are further estimated to boost the demand for regenerative medicines in the U.S. during the forecast period. Moreover, growing research and development practices, along with the increase in ambulatory surgical centers in the country are anticipated to influence the regenerative medicines market positively in the coming years. DOWNLOAD SAMPLE REPORT HERE
The market in Europe is segmented on the basis of country into Germany, U.K., France, Italy, Spain, Turkey, Russia, and Rest of Europe, out of which, the market in Germany is anticipated to hold the largest market share of 23.28% in the year 2029 and further attain a revenue of USD 15502.53 Million in the same period. Growing healthcare expenditure in the country, along with the increasing focus of the government on prioritizing healthcare services for its citizens, and the need for qualitative healthcare services amongst individuals are some of the major factors anticipated to drive the market growth in the country.
The global regenerative medicine market is segmented by therapy into cell therapy, gene therapy, tissue engineering, small molecule & biologic, and others. Out of these, the cell therapy segment is expected to hold the largest market share throughout the forecast period and further attain a revenue of USD 100,165 Million by the end of 2029, up from USD 19,608.88 Million in 2020. The segment is also anticipated to grow with the highest CAGR of 17% during the forecast period. Based on material, the market is segmented into synthetic material, biologically derived material, genetically engineered material, and others, out of which, the biologically derived material segment is expected to register the largest revenue of USD 76715 Million by the end of 2029 by growing with the highest CAGR of 17.52% during the forecast period. The biologically derived material segment is further segmented into collagen, xenogenic material, and other, out of which, the collagen segment is expected to grab the largest market revenue of USD 41809.68 Million by the end of 2029. The segment is also expected to grow with the highest CAGR of 18.92% during the forecast period. Based on application, the market is segmented into cardiovascular, oncology, dermatology, musculoskeletal, wound healing, ophthalmology, neurology, and others. Amongst these segments, the oncology segment is expected to hold the largest market share by attaining a revenue of USD 73616.25 Million by the end of 2029, up from USD 14859.98 Million in 2020. The market is also segmented by end user into hospitals, clinics, and others. Out of these, the hospitals segment is expected to hold the majority of the market share and further attain a revenue of USD 111387.50 Million by the end of 2029.
Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the global regenerative medicine market that are included in our report are Amgen Inc., Novartis AG, Medtronic Plc., Stryker Corporation, CryoLife, Inc., Integra LifeSciences Corporation, 3M Company, AbbVie Inc., Zimmer Biomet, and others.
FREQUENTLY ASKED QUESTIONS
The rising incidences of cancer, diabetes and cardiovascular disease along with the rise in research activities are the major factors responsible for the growth of the market.
The market is anticipated to attain a CAGR of 16.43% over the forecast period i.e., 2021-2029.
High cost of treatment and stringent government policies are estimated to act as barriers to the market growth.
Europe is estimated to create notable opportunities for market growth over the forecast period.
The major players in the market Amgen Inc., Novartis AG, Medtronic Plc., Stryker Corporation, CryoLife, Inc., Integra LifeSciences Corporation, 3M Company, AbbVie Inc., Zimmer Biomet, and others.
The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by therapy, material, application, end-user, and by region.
The hospital segment is anticipated to hold largest market size in value and is estimated to display significant growth opportunities.
Related Reports
Disclaimer | Privacy Policy | Terms & Conditions
Copyright © 2021 Research Nester. All Rights Reserved
